NEW YORK (GenomeWeb News) – Codon Devices will work with Merrimack Pharmaceuticals to develop therapeutic proteins under a research, development, and license agreement, Codon said today.
Codon will use its BioLogic platform to engineer proteins for specifications set by Merrimack, which is developing therapeutic products aimed at autoimmune disease and cancer.
Merrimack will pay Codon clinical milestone payments and royalties on net sales of any protein products that may result from the agreement.